By Moitreyee Chatterjee-Kishore, Ph.D., MBA, Head of Oncology Development, Astellas Pharma Inc. | How targeted protein degraders could eliminate KRAS and redefine cancer care – insights from Astellas’ Head of Oncology Development
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Targeted protein degradation is changing how drug discovery teams think about disease biology. For many years, small molecule…
As Bristol Myers Squibb attempts to convert two accelerated oncology nods for Krazati into traditional FDA approvals, the company…
Combination strategies are rapidly redefining treatment for HER2-positive solid tumors. | HER2 combination strategies are…
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by…
Verastem eyes accelerated approval for KRAS G12D drug in 3 cancers; ADC Therapeutics cuts 17% of staff in restructuring.
Modern drug development demands faster, more scalable gene expression insights. Download this white paper to explore how…
